ACXP vs. NRXP, BCTX, FBIO, APRE, SPRB, APLM, DARE, IPA, VIRX, and THTX
Should you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include NRx Pharmaceuticals (NRXP), BriaCell Therapeutics (BCTX), Fortress Biotech (FBIO), Aprea Therapeutics (APRE), Spruce Biosciences (SPRB), Apollomics (APLM), Daré Bioscience (DARE), ImmunoPrecise Antibodies (IPA), Viracta Therapeutics (VIRX), and Theratechnologies (THTX). These companies are all part of the "pharmaceutical preparations" industry.
Acurx Pharmaceuticals (NASDAQ:ACXP) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation.
In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 12 mentions for Acurx Pharmaceuticals and 10 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.37 beat Acurx Pharmaceuticals' score of 0.07 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.
11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 35.3% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 21.1% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Acurx Pharmaceuticals has a beta of -1.79, meaning that its stock price is 279% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
Acurx Pharmaceuticals presently has a consensus price target of $12.00, suggesting a potential upside of 455.56%. Given Acurx Pharmaceuticals' higher probable upside, equities research analysts clearly believe Acurx Pharmaceuticals is more favorable than NRx Pharmaceuticals.
Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Acurx Pharmaceuticals received 4 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 91.67% of users gave Acurx Pharmaceuticals an outperform vote.
NRx Pharmaceuticals' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.
Summary
Acurx Pharmaceuticals beats NRx Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Acurx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acurx Pharmaceuticals Competitors List
Related Companies and Tools
